Clinical trial · no report yet · Phase 3
ZEAL-1L
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
- NCT04475939 ↗
- Completed
- GlaxoSmithKline
- 6 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Niraparib; Pembrolizumab; Placebo
- Arms
- Participants receiving niraparib plus pembrolizumab · Experimental
- Participants receiving placebo plus pembrolizumab · Placebo comparator
- Enrollment
- 666
- Primary outcomes
- Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population
- Sponsor
- GlaxoSmithKline
- Start
- Oct 26, 2020
- Primary completion
- Feb 26, 2025
- Results posted
- Yes
- Registry record
- NCT04475939 · updated Jun 18, 2026
Publications
linked from the registry- Ramalingam SS, Velcheti V, Altan M, de Castro G Jr, Thomas M, Sanborn RE, Mazieres J, Schuler M, Isaksson J, Schenker M, Poddubskaya E, Kim YJ, Parakh S, Liu W, Neibauer MW, Aghera V, Chiu G, Peters S. Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L). J Thorac Oncol. 2026 Jul 10:104087. doi: 10.1016/j.jtho.2026.104087. Online ahead of print. PubMed 42431263
- Ramalingam SS, Thara E, Awad MM, Dowlati A, Haque B, Stinchcombe TE, Dy GK, Spigel DR, Lu S, Iyer Singh N, Tang Y, Teslenko I, Iannotti N. JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. Cancer. 2022 Jan 1;128(1):65-74. doi: 10.1002/cncr.33885. Epub 2021 Sep 3. PubMed 34478166